ArticleInternational journal of cell biology2013
Alternative splicing programs in prostate cancer.
Article in International journal of cell biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 29 citations in OpenAlex.
- Tumor-promoting effect and tumor immunity of SRSFs.Frontiers in cell and developmental biology · 2025Review
- The androgen receptor couples promoter recruitment of RNA processing factors to regulation of alternative polyadenylation at the 3' end of transcripts.Nucleic acids research · 2022Article
- The DNA/RNA helicase DHX9 contributes to the transcriptional program of the androgen receptor in prostate cancer.Journal of experimental & clinical cancer research : CR · 2022Article
- Nanovectorization of Prostate Cancer Treatment Strategies: A New Approach to Improved Outcomes.Pharmaceutics · 2021Review
- A new compound targets the AF-1 of androgen receptor and decreases its activity and protein levels in prostate cancer cells.American journal of cancer research · 2020Article
- Serine/arginine-rich splicing factors: the bridge linking alternative splicing and cancer.International journal of biological sciences · 2020Review
- c-MYC empowers transcription and productive splicing of the oncogenic splicing factor Sam68 in cancer.Nucleic acids research · 2019Article
- Unveiling novel targets of paclitaxel resistance by single molecule long-read RNA sequencing in breast cancer.Scientific reports · 2019Article
- Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers.PLoS computational biology · 2019Review
- Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Comprehensive investigation of alternative splicing and development of a prognostic risk score for prostate cancer based on six-gene signatures.Journal of Cancer · 2019Article
- Role of Alternative Splicing in Prostate Cancer Aggressiveness and Drug Resistance in African Americans.Advances in experimental medicine and biology · 2019Review
- A k-mer based transcriptomics approach for antisense drug discovery targeting the Ewing's family of tumors.Oncotarget · 2018Article
- Targeting Splicing in Prostate Cancer.International journal of molecular sciences · 2018Review
- RNA splicing and splicing regulator changes in prostate cancer pathology.Human genetics · 2017Review
- Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer.Molecular cancer research : MCR · 2015Article
- Connecting the speckles: Splicing kinases and their role in tumorigenesis and treatment response.Nucleus (Austin, Tex.) · 2015Review
- The functional landscape of Hsp27 reveals new cellular processes such as DNA repair and alternative splicing and proposes novel anticancer targets.Molecular & cellular proteomics : MCP · 2014Article
- The structural basis for cancer treatment decisions.Oncotarget · 2014Review
- Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases.Chemical reviews · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) remains one of the most frequent causes of death for cancer in the male population. Although the initial antiandrogenic therapies are efficacious, PCa often evolves into a hormone-resistant, incurable disease. The genetic and phenotypic heterogeneity of this type of cancer renders its diagnosis and cure particularly challenging. Mounting evidence indicates that alternative splicing, the process that allows production of multiple mRNA variants from each gene, contributes to the heterogeneity of the disease. Key genes for the biology of normal and neoplastic prostate cells, such as those encoding for the androgen receptor and cyclin D1, are alternatively spliced to yield protein isoforms with different or even opposing functions. This review illustrates some examples of genes whose alternative splicing regulation is relevant to PCa biology and discusses the possibility to exploit alternative splicing regulation as a novel tool for prognosis, diagnosis, and therapeutic approaches to PCa.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.